209 CUPRINS

18. Kavey RE, Daniels SR, Lauer RM, Atlins DL, Hayman LL, Taubert K. American
Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease
beginning in childhood. // Circulation, 2003; 107:1562-6.
19. Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of multiple risk factor
pro les on determining cardiovascular disease risk. //Prev Med, 1998; 27:1-9.
20. Lehr HA, Sagban TA, Ihling C, Zahringer U.,Hungerer KD, Blumrich M., Reifenberg
K.,Bhakdi S. Immunnopathogenesis of atherosclerosis in rsbbits on hypercholesterolemic diet.//
Circulation, 2001;104: 914-920.
21. Oганов Р.Г. Факторы риска и профилактика сердечно-сосудистых заболеваний.
Качество жизни. //М. Медицина, 2003; 210-24.
22. Hunt SA, Abraham WT, Chin MH, Feldman AM et al. ACC/AHA 2005 ghuideline
update for the diagnosis and management of chronic heart failure in the adult: a report of
the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. //Circulation, 2005;112:1825-1852.
23. Ross RD. Medical management of chronic hearth failure in children. //American
Journal Cardiovascular Drugs, 2001; 1(1):37-44.
24. Rosenthal D , Chrisant MR , Edens E. International Society for Heart and Lung
Transplantation: Practice guidelines for management of heart failure in children. //J Heart Lung
Transplant, 2004; 23:1313-33.
25. Shaddy RE. In: Pediatric Heart failure: Medical management of chronic systolic left
ventricular dysfunction in children. //2005;Taylor & Francis Group: 589-619.
26. Ridker P.M., Cushman M, et al. Plasma concentration of CRP and risk of developing
peripheral vascular disease.// Circulation, 1998; 97: 425-8.
27. Ridker P.M., Hennekens CH, Buring JE, Rifai N. C-reactive protein and other marcers
of in ammation in the prediction of cardiovascular disease in women. //N Engl J Med, 2000;
342: 836-43.
28. Pauriah M, Struthers A D, Lang C C. Biomarkers and surrogate endpoints in
cardiovascular therapeutics research: under scrutiny following results of the ENHANCE study.//
Cardiovasc Ther, 2008; 26: 85-8.
29. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and
rupture. //Ateroscler Tromb Vasc Biol, 2007; 27:15-26.
30. Muviel A. Cytokine regulation of metalloproteinase gene expression. //J.Cell Biochem,
1993; 53: 288-95.
31. BRAUNWALD, E. Heart disease. A textbook of cardiovascular medicine/5th edition.
1997; 853 p.
32. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe
congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival
Study (CONSENSUS).// N Engl J Med., 1987; 316:s1429-1435.
33